Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.

The increase on CDR-SB score was 1.22 for Leqembi and 1.75 for a dummy drug, where higher numbers indicate greater impairment. Leqembi's vial design could result in hundreds of millions in annual ...

Eisai has lowered the sales forecast for its Alzheimer’s drug Leqembi (lecanemab), primarily citing delays in revenue in the US. The Japanese pharma expects its lead product co-developed with ...

The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Leqembi ... in their CDR-SB score, while those ...

Leqembi (lecanemab-irmb) is a medication doctors prescribe for people with Alzheimer’s disease. Original Medicare Part B covers the drug because you can receive it as an intravenous (IV) infusion.

Slightly lower than the last score the phone allegedly managed, but still very impressive. Mind you, as far as we know, AnTuTu never shows 100%, so this is as good as it gets. Just as a reminder ...

The EMA stated: “After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive ...

The stock is down 29 percent this year as of Tuesday’s close, largely due to a sluggish start for Leqembi — on the market to treat Alzheimer’s since January 2023 — and the recent rejection ...

A European Medicines Agency committee had said in July that the medicine, called Leqembi, should be rejected, citing the modest benefits seen in trials and the potentially dangerous side effects ...